Pieris Pharmaceuticals Faces Agreement Termination and Pursues New Opportunities
Company Announcements

Pieris Pharmaceuticals Faces Agreement Termination and Pursues New Opportunities

The latest announcement is out from Pieris Pharmaceuticals (PIRS).

Pieris Pharmaceuticals, Inc. has received a notice from Les Laboratoires Servier to terminate their collaborative agreement on Anticalin-based therapeutics due to safety concerns from a Phase 1 clinical study. This termination will also end the associated Non-Exclusive License Agreement, effective December 27, 2024. Despite this setback, Pieris Pharmaceuticals still has the potential to earn significant milestones and royalties through other partnerships, with possible milestone payments reaching up to $200 million and commercial milestones over $415 million for its 4-1BB bispecific Mabcalin protein assets, developed with Boston Pharmaceuticals and Pfizer Inc. The company is also exploring strategic opportunities to enhance stockholder value.

See more data about PIRS stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyPieris Pharmaceuticals announces first patient dosed in SELVA Phase 3 trial
TheFlyPalvella Therapeutics apponts Matthew Korenberg as CFO
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App